Applying a cold compress to the injection site may alleviate local discomfort
doi:10.1111/dom.15566 25
If a vendor suggests dosing, shares user testimonials, or implies cosmetic benefit, they collapse the distinction, and regulatory agencies treat the product as an unapproved drug
As an SGLT2 inhibitor, ertugliflozin carries the same warnings as others in the class, including the potential for elevations in LDL cholesterol, as well as an increased risk of ketoacidosis, acute kidney injury and renal failure, urosepsis and pyelonephritis, genital mycotic infections, lower-limb amputation, and severe hypotension
Assess baseline status during breaks to evaluate sustained benefits versus temporary effects
Quintanilla et al